Table 2.

Endocrine treatment patterns at the end of life of women who died with hormone receptor-positive metastatic breast cancer, aged ≥65 years in Sweden, 2016-2020.

End-of-life treatment patterns	Overall (n=3098)	Prevalent users 12 to 3 months before death (n=2185)	Non-users 12 to 3 months before death (n=913)
Continuation	1217 (39.3%)	1217 (55.7%)	n/a
Discontinuation	968 (31.2%)	968 (44.4%)	n/a
Initiation	157 (5.1%)	n/a	157 (17.2%)
No use	756 (24.4%)	n/a	756 (82.8%)

n/a = not applicable.